Ovarian Serous Adenocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Ovarian Cancer (527)

›

BRAF V600E	Ovarian Serous Adenocarcinoma	BRAF V600E	Ovarian Serous Adenocarcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + docetaxel + letrozole Sensitive: A2 - Guideline carboplatin + docetaxel + letrozole Sensitive : A2	carboplatin + docetaxel + letrozole Sensitive: A2 - Guideline carboplatin + docetaxel + letrozole Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2
BRAF V600E	Ovarian Serous Adenocarcinoma	BRAF V600E	Ovarian Serous Adenocarcinoma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRCA2 mutation	Ovarian Serous Adenocarcinoma	BRCA2 mutation	Ovarian Serous Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	olaparib + ACR-368 Sensitive: C2 – Inclusion Criteria olaparib + ACR-368 Sensitive : C2	olaparib + ACR-368 Sensitive: C2 – Inclusion Criteria olaparib + ACR-368 Sensitive : C2
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
BRCA2 mutation	Ovarian Serous Adenocarcinoma	BRCA2 mutation	Ovarian Serous Adenocarcinoma	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12A	Ovarian Serous Adenocarcinoma	KRAS G12A	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
Choline elevation	Ovarian Serous Adenocarcinoma	Choline elevation	Ovarian Serous Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
SERPINE1 expression	Ovarian Serous Adenocarcinoma	SERPINE1 expression	Ovarian Serous Adenocarcinoma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
BRCA2 deletion	Ovarian Serous Adenocarcinoma	BRCA2 deletion	Ovarian Serous Adenocarcinoma	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
BRCA1 deletion	Ovarian Serous Adenocarcinoma	BRCA1 deletion	Ovarian Serous Adenocarcinoma	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	AZD1775 Sensitive: C4 – Case Studies AZD1775 Sensitive : C4	AZD1775 Sensitive: C4 – Case Studies AZD1775 Sensitive : C4
GOPC-ROS1 fusion	Ovarian Serous Adenocarcinoma	GOPC-ROS1 fusion	Ovarian Serous Adenocarcinoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ER Y537N	Ovarian Serous Adenocarcinoma	ER Y537N	Ovarian Serous Adenocarcinoma	fulvestrant Sensitive: C4 – Case Studies fulvestrant Sensitive : C4	fulvestrant Sensitive: C4 – Case Studies fulvestrant Sensitive : C4
TMB-H + MSH6 F1088fs	Ovarian Serous Adenocarcinoma	TMB-H + MSH6 F1088fs	Ovarian Serous Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	binimetinib + PF-07284892 Sensitive: C4 – Case Studies binimetinib + PF-07284892 Sensitive : C4	binimetinib + PF-07284892 Sensitive: C4 – Case Studies binimetinib + PF-07284892 Sensitive : C4
BRCA2 mutation	Ovarian Serous Adenocarcinoma	BRCA2 mutation	Ovarian Serous Adenocarcinoma	ACR-368 + LY3023414 Sensitive: D – Preclinical ACR-368 + LY3023414 Sensitive : D	ACR-368 + LY3023414 Sensitive: D – Preclinical ACR-368 + LY3023414 Sensitive : D
BRAF L485-P490 deletion	Ovarian Serous Adenocarcinoma	BRAF L485-P490 deletion	Ovarian Serous Adenocarcinoma	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
PRMT1 underexpression	Ovarian Serous Adenocarcinoma	PRMT1 underexpression	Ovarian Serous Adenocarcinoma	carboplatin Sensitive: D – Preclinical carboplatin Sensitive : D	carboplatin Sensitive: D – Preclinical carboplatin Sensitive : D
PRMT1 underexpression	Ovarian Serous Adenocarcinoma	PRMT1 underexpression	Ovarian Serous Adenocarcinoma	cisplatin Sensitive: D – Preclinical cisplatin Sensitive : D	cisplatin Sensitive: D – Preclinical cisplatin Sensitive : D
KRAS wild-type	Ovarian Serous Adenocarcinoma	KRAS wild-type	Ovarian Serous Adenocarcinoma	VS-6766 + VS-4718 Sensitive: D – Preclinical VS-6766 + VS-4718 Sensitive : D	VS-6766 + VS-4718 Sensitive: D – Preclinical VS-6766 + VS-4718 Sensitive : D
RAF1 V207G	Ovarian Serous Adenocarcinoma	RAF1 V207G	Ovarian Serous Adenocarcinoma	VS-6766 + VS-4718 Sensitive: D – Preclinical VS-6766 + VS-4718 Sensitive : D	VS-6766 + VS-4718 Sensitive: D – Preclinical VS-6766 + VS-4718 Sensitive : D
KRAS wild-type	Ovarian Serous Adenocarcinoma	KRAS wild-type	Ovarian Serous Adenocarcinoma	VS-4718 Sensitive: D – Preclinical VS-4718 Sensitive : D	VS-4718 Sensitive: D – Preclinical VS-4718 Sensitive : D
RAF1 V207G	Ovarian Serous Adenocarcinoma	RAF1 V207G	Ovarian Serous Adenocarcinoma	VS-4718 Sensitive: D – Preclinical VS-4718 Sensitive : D	VS-4718 Sensitive: D – Preclinical VS-4718 Sensitive : D

Ovarian Serous Adenocarcinoma

Associations(31)

Associations
(31)